News and Publications

2022 Refresher Course reg opens, COVID-19 clinical guidelines, New ASTRO/ACS research grant

January 12, 2022

Registration now open for 2022 ASTRO Annual Refresher Course
The ASTRO Annual Refresher Course, an interactive virtual conference, will take place March 25-27, 2022. Join your colleagues for this practical meeting that provides a comprehensive review of the latest treatment methods and core competencies for the major disease sites, with a look at the emerging trends and technologies that may impact daily practice. The format combines recorded sessions with Live Q&A, and the program includes a variety of networking opportunities for attendees and a virtual exhibit hall. Register by February 16 to take advantage of early-bird rates.

Reminder: ASTRO COVID-19 clinical guidelines
As the Omicron variant surges, we wanted to remind you of ASTRO’s COVID-19 clinical guidelines. When the COVID-19 pandemic first hit in March 2020, ASTRO compiled resources developed by clinical teams and based on the best available information at the time they were posted. Since that time, the COVID-19 vaccine and booster became available. Additionally, the CDC has imposed new isolation and quarantine guidelines. You and your patients should consult the CDC, your institution’s infection control protocol and state and local public health rules for guidance regarding quarantine, isolation, face coverings and vaccines.

Review the topics and speakers for the 2022 Multidisciplinary Head and Neck Cancers Symposium
View the schedule of events for the topics and world-class speakers we have arranged for the 2022 Multidisciplinary Head and Neck Cancers Symposium being held in Phoenix, Arizona, from February 24-26, 2022. Reserve your room by February 4 at the highly rated JW Marriott Phoenix Desert Ridge Resort and Spa to receive the discounted room rate. And be sure to register before February 2 to receive the advance rate. Join your colleagues for this interactive and engaging symposium that features the latest in head and neck cancers research and treatments.

New research grant call for applications: ASTRO-ACS Clinician Scientist Development Grant
ASTRO is pleased to announce a new Clinician Scientist Development Grant (CSDG) in partnership with the American Cancer Society (ACS). The goal of the ASTRO-ACS CSDG is to foster the research career of a clinician scientist in radiation oncology. Minimally, an applicant must be within the first six years of an initial full-time U.S. faculty appointment and either have a clinical doctoral degree with an active license to provide clinical care or be a medical physicist with a clinical license at the time of the application. The award may be for three to five years with $135,000/year for direct costs, plus 8% allowable indirect costs. View detailed eligibility criteria and application instructions on the ACS CSDG website. For questions, email the ASTRO Department of Scientific Affairs or ACS at grant.eligibility@cancer.org. The application deadline is April 1, 2022. All other ASTRO grant applications are due Feb 11, 2022.

Set a 2022 goal to get APEx accredited
Join the fastest growing accreditation program and be listed among the APEx accredited practices. APEx is the right choice for any radiation oncology practice, and the results are worth the effort, not only for your practice but also for your patients. ASTRO President Geraldine Jacobson, MD, MPH, MBA, FASTRO, has said of her experience with APEx, “We selected APEx because we viewed their accreditation structure as a vehicle to improve our practice quality. Meeting the APEx Standards has been a valuable process for every aspect of our workflow and improved our quality and coordination of care.”

Select a time convenient for you for a one-on-one meeting to learn more about APEx Accreditation. ASTRO staff look forward to talking to you and helping your practice achieve APEx accreditation in 2022.

ASTRO urges Congress to increase investments in cancer research
ASTRO, along with 49 other member organizations of the One Voice Against Cancer coalition, sent a joint letter to leadership of the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies asking for the prioritization of funding for cancer research and prevention. The coalition specifically asks for $7.609 billion for the National Cancer Institute, $51.733 billion for the National Institutes of Health, and $559 million for the CDC Division of Cancer Prevention and Control. For more details from the letter, see What’s Happening in Washington.

New Online SA-CME course available at the ASTRO Academy: Challenging Cases in Cervix Cancer
Challenging Cases in Cervix Cancer - 2021 Annual Meeting presents challenging cases either due to poorly studied disease subsets, newer advances in standard intracavitary brachytherapy, technically challenging distributions of disease or newly controversial subjects in when and how radiation therapy should be used and integrated with systemic therapy. This activity provides 1.25 AMA PRA Category 1 CreditTM and is available through 11:59 p.m. Eastern time, January 9, 2025.

New President and Vice President to lead ROI
The ROI Board of Trustees welcomed new officers: President Colleen A.F. Lawton, MD, FASTRO, and Vice President Gita Suneja, MD, MSHP, who both began three-year terms of service on January 1. Dr. Lawton is professor and vice chair of the Department of Radiation Oncology at the Medical College of Wisconsin and the recent recipient of the ASTRO Gold Medal. A longtime and passionate advocate, Dr. Lawton helped launch the ROI and served as Vice President for a total of nine years. Dr. Suneja is associate professor and physician-scientist in the Department of Radiation Oncology at the Huntsman Cancer Institute at the University of Utah. She led the ROI Research Committee as chair from 2018 to 2021, overseeing a period of significant growth in the number and diversity of research grants awarded.

Call for papers: Red Journal focus issue on oligometastasis
Since the 1990s, oncologists have increasingly recognized the unique phenomenon of oligometastatic disease. Standard definitions and the proper application of therapies remain topics of active debate, with high likelihood that these may differ across histologies and mode of presentation. The Red Journal proposes an in-depth examination of all aspects of oligometastasis as approached by the clinic, biology and physics, with the aim of publishing a focus issue devoted to the subject in the latter half of 2022. Please refer to the full Call for Papers, and contact the Red Journal editorial office with any questions.

Correction: ASCO/SNO/ASTRO guideline link
In last week’s ASTROgram, the incorrect link was used for the newly released guideline on brain metastases. Please view the joint guideline in the Journal of Clinical Oncology: Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.